{"analyses":[{"ciLowerLimit":"0.26","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.02","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.70","paramType":"Hazard Ratio (HR)","paramValue":"0.52","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median overall survival has not been reached.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median overall survival has not been reached.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"229"}],"units":"Participants"}],"description":"Overall Survival was measured from the date of randomization to date of death due to any cause. OS was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Beginning between day 100-110, patients receive oral lenalidomide once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.","id":"OG000","title":"Lenalidomide Maintenance"},{"description":"Beginning between day 100-110, patients receive oral placebo once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.\n\n(closed as of 12/17/09)","id":"OG001","title":"Placebo Maintenance"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 10 years)","title":"Overall Survival","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}